The government has so far paid Emergent BioSolutions $271 million, even though American regulators have yet to clear a single dose of vaccine produced at its manufacturing plant in Baltimore.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register. By continuing to use this site, you are consenting to our use of cookies.